Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund lessened its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 4.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 86,577 shares of the life sciences company’s stock after selling 3,956 shares during the period. New York State Common Retirement Fund owned approximately 0.11% of Integra LifeSciences worth $3,770,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Signaturefd LLC boosted its holdings in Integra LifeSciences by 248.5% in the fourth quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock valued at $25,000 after purchasing an additional 415 shares during the last quarter. Gladius Capital Management LP acquired a new stake in Integra LifeSciences during the third quarter valued at approximately $47,000. Covestor Ltd raised its stake in Integra LifeSciences by 82.5% during the third quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock valued at $78,000 after buying an additional 921 shares in the last quarter. International Assets Investment Management LLC acquired a new stake in shares of Integra LifeSciences during the 4th quarter worth approximately $190,000. Finally, Empirical Asset Management LLC acquired a new stake in shares of Integra LifeSciences during the 4th quarter worth approximately $212,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Wall Street Analyst Weigh In

IART has been the topic of a number of research reports. StockNews.com cut Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Tuesday, April 30th. Truist Financial dropped their price target on Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a research report on Friday, March 1st. JMP Securities dropped their price target on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a research report on Thursday, February 29th. Finally, Citigroup upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price target on the stock in a research report on Wednesday, April 3rd. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $44.89.

Integra LifeSciences Stock Performance

Shares of NASDAQ IART opened at $28.89 on Monday. The stock has a fifty day moving average price of $33.75 and a two-hundred day moving average price of $38.44. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45. The firm has a market cap of $2.27 billion, a P/E ratio of 34.81, a PEG ratio of 0.87 and a beta of 1.17. Integra LifeSciences Holdings Co. has a 1 year low of $27.18 and a 1 year high of $51.12.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). The firm had revenue of $397.00 million for the quarter, compared to the consensus estimate of $399.30 million. Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The business’s revenue for the quarter was down .3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.94 earnings per share. Research analysts forecast that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.